Allena Pharmaceuticals, Inc

(NASDAQ:ALNA)

Latest On Allena Pharmaceuticals, Inc (ALNA):

Date/Time Type Description Signal Details
2022-07-19 13:06 ESTNewsFirst two cohorts enrolled in Allena's phase 2a trial of gout & kidney disease treatmentN/A
2022-07-06 02:19 ESTNewsAllena Pharma reschedules special meeting to approve reverse stock split, shares fallN/A
2022-05-12 12:17 ESTNewsNano cap stock Allena surges on heavy volumeN/A
2022-05-04 22:12 ESTNewsAllena Pharmaceuticals $2.8M direct offeringN/A
2022-03-22 16:06 ESTNewsAllena extends losses on plans to end trial for lead asset and financial concernsN/A
2022-03-22 16:05 ESTNewsAllena downgraded to Neutral at B. Riley citing the end to lead clinical programN/A
2022-01-08 10:53 ESTNewsAllena Pharmaceuticals: A Double [Or More] Or Kaput In The Next 90 DaysN/A
2022-01-04 08:53 ESTNewsAllena Pharma jumps 55% after providing an update on gout treatmentN/A
2021-11-11 00:43 ESTNewsAllena Pharmaceuticals EPS beats by $0.01N/A
2021-11-04 03:28 ESTNewsAllena Pharmaceuticals' shares rise 9% after FDA Fast Track status for ALLN-346N/A
2021-10-07 04:05 ESTNewsALNA is at high risk of performing badlyN/A
2021-09-29 09:30 ESTNewsAllena Pharmaceuticals gets dosing underway in mid-stage ALLN-346 kidney disease trialN/A
2021-09-27 12:15 ESTNewsWarning: ALNA has been downgraded to Very BearishN/A
2021-09-21 11:21 ESTNewsWarning: ALNA has been downgraded to Very Bearish.N/A
2021-08-10 19:56 ESTNewsAllena Pharmaceuticals EPS misses by $0.03N/A
2021-07-20 18:12 ESTNewsAllena Pharma provides update on clinical development programs: ALLN-346 and ALLN-177N/A
2021-07-20 18:09 ESTNewsAllena Pharma launches $28M direct offeringN/A
2021-03-10 19:05 ESTFinancialsCompany financials have been released.Neutral
2021-03-10 11:04 ESTEarnings EstimateAn EPS average of -$0.19 is estimated for the quarter ending on June 30, 2021.Buy
2021-03-10 11:04 ESTEarnings EstimateAn EPS average of -$0.80 is estimated for the 2022 year.Sell
2021-03-09 12:10 ESTNewsAllena Pharmaceuticals EPS misses by $0.05N/A
2021-01-26 19:53 ESTNewsAllena Pharmaceuticals is up as AIGH Capital reveals 8% stakeN/A
2020-12-31 07:04 ESTAnalyst RatingThe Analyst Target Price has increased from $5.67 to $5.8.Buy
2020-12-13 03:08 ESTFinancialsCompany financials have been released.Neutral
2020-12-11 15:07 ESTFinancialsCompany financials have been released.Neutral
2020-12-04 03:05 ESTAnalyst RatingThe Analyst Target Price has decreased from $5.83 to $5.67.Neutral
2020-12-02 15:23 ESTNewsAllena Pharmaceuticals announces $10M bought dealN/A
2020-12-02 15:22 ESTNewsAllena Pharmaceuticals upsizes bought deal offering to $13MN/A
2020-12-01 09:57 ESTNewsAllena Pharma's ALLN-346 shows encouraging action in early-stage studyN/A
2020-11-25 11:11 ESTFinancialsCompany financials have been released.Neutral
2020-11-16 03:06 ESTAnalyst RatingThe Analyst Target Price has decreased from $7.83 to $5.83.Neutral
2020-11-12 03:05 ESTFinancialsCompany financials have been released.Neutral
2020-11-10 05:42 ESTNewsAllena Pharmaceuticals EPS misses by $0.01N/A
2020-11-10 03:06 ESTEarnings EstimateAn EPS average of -$0.22 is estimated for the quarter ending on March 31, 2021.N/A
2020-11-01 16:57 ESTFinancialsCompany financials have been released.Neutral
2020-10-03 08:07 ESTAnalyst RatingThe Analyst Target Price has increased from $7.67 to $7.83.Buy
2020-10-01 04:09 ESTNewsAllena Pharma rallies on convertible debt fundingN/A
2020-09-26 04:09 ESTFinancialsCompany financials have been released.Neutral
2020-09-09 11:32 ESTNewsAllena Pharma advances with its early-stage study for ALLN-346 in hyperuricemiaN/A
2020-08-26 12:05 ESTAnalyst RatingThe Analyst Target Price has decreased from $9 to $7.67.Neutral
2020-08-07 12:06 ESTFinancialsCompany financials have been released.Neutral
2020-08-06 09:47 ESTNewsAllena Pharmaceuticals EPS beats by $0.02N/A
2020-07-31 00:07 ESTFinancialsCompany financials have been released.Neutral
2020-07-28 15:46 ESTFinancialsCompany financials have been released.Neutral
2020-07-28 15:21 ESTNewsAllena Pharma secures $5M capital raiseN/A
2020-07-28 15:21 ESTNewsAllena Pharma raises bought deal offering to $6.7MN/A
2020-07-23 16:11 ESTFinancialsCompany financials have been released.Neutral
2020-07-07 12:04 ESTAnalyst RatingThe Analyst Target Price has decreased from $9.25 to $9.Neutral
2020-06-03 20:38 ESTNewsAllena Pharmaceuticals announces $15M registered direct offeringN/A
2020-06-02 12:04 ESTEarnings EstimateAn EPS average of -$0.26 is estimated for the quarter ending on September 30, 2020.Buy

About Allena Pharmaceuticals, Inc (ALNA):

Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic that is in phase 3 clinical program for the treatment of hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and moderate to severe chronic kidney diseases. Allena Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Newton, Massachusetts.

ALNA Quotes by TradingView

See Advanced Chart

General

  • Name Allena Pharmaceuticals, Inc
  • Symbol ALNA
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 41
  • Fiscal Year EndDecember
  • IPO Date2017-11-02
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.allenapharma.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 4.36
  • Enterprise Value EBITDA 0.08
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.82
  • Next Year EPS Estimate -$0.95
  • Next Quarter EPS Estimate -$0.18
  • Return on Assets -55%
  • Return on Equity -165%
  • Earnings Per Share -$2.01
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 90.44 million
  • EBITDA -42249000
  • Analyst Target Price $5.8
  • Book Value Per Share $0.44
View More

Share Statistics

  • Shares Outstanding 50.25 million
  • Shares Float 47.76 million
  • % Held by Insiders 388%
  • % Held by Institutions 42.24%
  • Shares Short 663917
  • Shares Short Prior Month 902093
  • Short Ratio 0.15
  • Short % of Float 2%
  • Short % of Shares Outstanding 1%
View More

Technicals

  • Beta 2.31
  • 52 Week High $3.39
  • 52 Week Low $0.78
  • 50 Day Moving Average 1.78
  • 200 Day Moving Average 1.49
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Allena Pharmaceuticals, Inc (ALNA) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Allena Pharmaceuticals, Inc (ALNA) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-09$N/A-$0.24-$0.19-29.73%
2020-09-302020-11-09$N/A-$0.22-$0.21-5.52%
2020-06-302020-08-05$N/A-$0.26-$0.299.09%
2020-03-312020-05-13$N/A-$0.31-$0.4327.35%
2019-12-312020-03-16$N/A-$0.46-$0.5516.26%
2019-09-302019-11-13$N/A-$0.57-$0.50-13.91%
2019-06-302019-08-07$N/A-$0.54-$0.563%
2019-03-312019-05-08$N/A-$0.55-$0.49-12.5%
2018-12-312019-03-07$N/A-$0.46-$0.508.6%
2018-09-302018-11-07$N/A-$0.46-$0.460%
2018-06-302018-08-07$N/A-$0.42-$0.39-7.14%
2018-03-312018-05-08$N/A-$0.38-$0.417.77%
2017-12-312018-03-27$N/A-$0.48-$0.5410.7%
2017-09-302017-12-14$N/A-$0.30-$0.313.23%

Allena Pharmaceuticals, Inc (ALNA) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Allena Pharmaceuticals, Inc (ALNA) Chart:

Allena Pharmaceuticals, Inc (ALNA) News:

Below you will find a list of latest news for Allena Pharmaceuticals, Inc (ALNA) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Allena Pharmaceuticals, Inc (ALNA) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest ALNA Trades:

Date Shares Price
Jun 13, 2022 7:32 PM EST100$0.1283
Jun 13, 2022 7:32 PM EST300$0.1283
Jun 13, 2022 7:32 PM EST200$0.1283
Jun 13, 2022 7:32 PM EST200$0.1291
Jun 13, 2022 7:32 PM EST100$0.1284

Allena Pharmaceuticals, Inc (ALNA) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-09SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1624658/000121465920005483/0001214659-20-005483-index.htm
2018-12-07UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1624658/000000000018037485/0000000000-18-037485-index.htm
2018-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1624658/000031506618001020/0000315066-18-001020-index.htm
2018-09-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1624658/000031506618002306/0000315066-18-002306-index.htm
2020-02-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1624658/000031506620000807/0000315066-20-000807-index.htm
2018-07-11SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1624658/000089542118000485/0000895421-18-000485-index.htm
2019-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1624658/000089542119000086/0000895421-19-000086-index.htm
2019-12-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1624658/000089542119000660/0000895421-19-000660-index.htm
2020-03-30SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1624658/000089542120000291/0000895421-20-000291-index.htm
2020-05-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1624658/000089542120000333/0000895421-20-000333-index.htm
2019-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1624658/000089924319000577/0000899243-19-000577-index.htm
2019-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1624658/000089924319005943/0000899243-19-005943-index.htm
2019-12-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1624658/000089924319028519/0000899243-19-028519-index.htm
2019-12-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1624658/000089924319028520/0000899243-19-028520-index.htm
2020-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1624658/000089924320014585/0000899243-20-014585-index.htm
2020-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1624658/000089924320014586/0000899243-20-014586-index.htm
2020-10-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1624658/000089924320027640/0000899243-20-027640-index.htm
2020-10-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1624658/000089924320027641/0000899243-20-027641-index.htm
2018-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1624658/000107261318000146/0001072613-18-000146-index.htm
2020-02-11SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1624658/000110465920016240/0001104659-20-016240-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1624658/000110465920021669/0001104659-20-021669-index.htm
2019-12-12SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1624658/000110580619000029/0001105806-19-000029-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1624658/000110580620000009/0001105806-20-000009-index.htm
2018-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1624658/000114420418008868/0001144204-18-008868-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1624658/000114420419008384/0001144204-19-008384-index.htm
2018-01-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1624658/000119312518005084/0001193125-18-005084-index.htm
2018-02-13SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1624658/000119312518042534/0001193125-18-042534-index.htm
2018-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1624658/000119312518045930/0001193125-18-045930-index.htm
2018-02-15SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1624658/000119312518046108/0001193125-18-046108-index.htm
2018-03-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1624658/000119312518071359/0001193125-18-071359-index.htm
2018-03-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1624658/000119312518078314/0001193125-18-078314-index.htm
2018-03-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1624658/000119312518096681/0001193125-18-096681-index.htm
2018-03-27S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1624658/000119312518096802/0001193125-18-096802-index.htm
2018-04-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1624658/000119312518131283/0001193125-18-131283-index.htm
2018-04-25DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1624658/000119312518131306/0001193125-18-131306-index.htm
2018-04-25DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1624658/000119312518131313/0001193125-18-131313-index.htm
2018-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1624658/000119312518155283/0001193125-18-155283-index.htm
2018-06-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1624658/000119312518190520/0001193125-18-190520-index.htm
2018-06-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1624658/000119312518196420/0001193125-18-196420-index.htm
2018-07-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1624658/000119312518213782/0001193125-18-213782-index.htm
2018-07-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1624658/000119312518223150/0001193125-18-223150-index.htm
2018-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1624658/000119312518240427/0001193125-18-240427-index.htm
2018-08-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1624658/000119312518247815/0001193125-18-247815-index.htm
2018-11-15SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1624658/000119312518328145/0001193125-18-328145-index.htm
2018-12-03S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1624658/000119312518341159/0001193125-18-341159-index.htm
2018-12-21CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1624658/000119312518355143/0001193125-18-355143-index.htm
2018-12-27424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1624658/000119312518358504/0001193125-18-358504-index.htm
2019-01-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1624658/000119312519002528/0001193125-19-002528-index.htm
2019-03-07S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1624658/000119312519067214/0001193125-19-067214-index.htm
2019-04-26DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1624658/000119312519122375/0001193125-19-122375-index.htm
2019-04-26DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1624658/000119312519122402/0001193125-19-122402-index.htm
2019-06-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1624658/000119312519178143/0001193125-19-178143-index.htm
2019-06-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1624658/000119312519184922/0001193125-19-184922-index.htm
2019-06-28424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1624658/000119312519184947/0001193125-19-184947-index.htm
2019-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1624658/000119312519286673/0001193125-19-286673-index.htm
2019-11-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1624658/000119312519290551/0001193125-19-290551-index.htm
2020-02-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1624658/000119312520032190/0001193125-20-032190-index.htm
2020-03-16S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1624658/000119312520075038/0001193125-20-075038-index.htm
2020-06-05424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1624658/000119312520161903/0001193125-20-161903-index.htm
2020-06-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1624658/000119312520161910/0001193125-20-161910-index.htm
2020-07-27424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1624658/000119312520199777/0001193125-20-199777-index.htm
2020-07-27FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1624658/000119312520199786/0001193125-20-199786-index.htm
2020-07-28FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1624658/000119312520200171/0001193125-20-200171-index.htm
2020-07-29424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1624658/000119312520202532/0001193125-20-202532-index.htm
2020-07-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1624658/000119312520202540/0001193125-20-202540-index.htm
2020-08-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1624658/000119312520234695/0001193125-20-234695-index.htm
2020-10-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1624658/000119312520260559/0001193125-20-260559-index.htm
2020-10-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1624658/000119312520263865/0001193125-20-263865-index.htm
2020-10-05DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1624658/000119312520263886/0001193125-20-263886-index.htm
2020-10-05DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1624658/000119312520263899/0001193125-20-263899-index.htm
2018-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1624658/000120919118009167/0001209191-18-009167-index.htm
2018-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1624658/000120919118009173/0001209191-18-009173-index.htm
2018-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1624658/000120919118009174/0001209191-18-009174-index.htm
2018-05-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1624658/000120919118029082/0001209191-18-029082-index.htm
2018-06-123Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1624658/000120919118037212/0001209191-18-037212-index.htm
2018-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1624658/000120919118037216/0001209191-18-037216-index.htm
2018-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1624658/000120919118037218/0001209191-18-037218-index.htm
2018-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1624658/000120919118037220/0001209191-18-037220-index.htm
2018-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1624658/000120919118037223/0001209191-18-037223-index.htm
2018-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1624658/000120919118037229/0001209191-18-037229-index.htm
2018-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1624658/000120919118037232/0001209191-18-037232-index.htm
2019-04-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1624658/000120919119024867/0001209191-19-024867-index.htm
2019-05-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1624658/000120919119027895/0001209191-19-027895-index.htm
2019-06-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1624658/000120919119035384/0001209191-19-035384-index.htm
2019-06-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1624658/000120919119035389/0001209191-19-035389-index.htm
2019-06-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1624658/000120919119035393/0001209191-19-035393-index.htm
2019-06-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1624658/000120919119035398/0001209191-19-035398-index.htm
2019-06-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1624658/000120919119035400/0001209191-19-035400-index.htm
2019-06-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1624658/000120919119035403/0001209191-19-035403-index.htm
2020-06-09SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1624658/000121465920005483/0001214659-20-005483-index.htm
2019-07-02SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1624658/000138713119004763/0001387131-19-004763-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1624658/000138713120001498/0001387131-20-001498-index.htm
2020-06-03SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1624658/000153561020000097/0001535610-20-000097-index.htm
2017-12-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1624658/000156459017024893/0001564590-17-024893-index.htm
2018-03-2710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1624658/000156459018006811/0001564590-18-006811-index.htm
2018-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1624658/000156459018011473/0001564590-18-011473-index.htm
2018-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1624658/000156459018019658/0001564590-18-019658-index.htm
2018-10-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1624658/000156459018023813/0001564590-18-023813-index.htm
2018-10-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1624658/000156459018024582/0001564590-18-024582-index.htm
2018-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1624658/000156459018027733/0001564590-18-027733-index.htm
2018-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1624658/000156459018027736/0001564590-18-027736-index.htm
2019-01-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1624658/000156459019000010/0001564590-19-000010-index.htm
2019-03-0710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1624658/000156459019006630/0001564590-19-006630-index.htm
2019-03-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1624658/000156459019006631/0001564590-19-006631-index.htm
2019-03-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1624658/000156459019007464/0001564590-19-007464-index.htm
2019-04-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1624658/000156459019011786/0001564590-19-011786-index.htm
2019-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1624658/000156459019016839/0001564590-19-016839-index.htm
2019-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1624658/000156459019016841/0001564590-19-016841-index.htm
2019-06-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1624658/000156459019021520/0001564590-19-021520-index.htm
2019-06-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1624658/000156459019021971/0001564590-19-021971-index.htm
2019-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1624658/000156459019029667/0001564590-19-029667-index.htm
2019-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1624658/000156459019029668/0001564590-19-029668-index.htm
2019-11-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1624658/000156459019043101/0001564590-19-043101-index.htm
2019-12-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1624658/000156459019045262/0001564590-19-045262-index.htm
2020-03-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1624658/000156459020010990/0001564590-20-010990-index.htm
2020-03-1610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1624658/000156459020010991/0001564590-20-010991-index.htm
2020-04-2910-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1624658/000156459020019432/0001564590-20-019432-index.htm
2020-05-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1624658/000156459020024852/0001564590-20-024852-index.htm
2020-05-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1624658/000156459020024854/0001564590-20-024854-index.htm
2020-08-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1624658/000156459020036448/0001564590-20-036448-index.htm
2020-08-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1624658/000156459020036450/0001564590-20-036450-index.htm
2018-12-26EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1624658/999999999518003235/9999999995-18-003235-index.htm

Allena Pharmaceuticals, Inc (ALNA) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Allena Pharmaceuticals, Inc (ALNA). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 388%
Institutional Ownership: 4224%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-05-09EDWARD WHOLIHANChief Financial OfficerBuy25,000.001.5939,750.0025,000.00https://www.sec.gov/Archives/edgar/data/1624658/000120919118029082/0001209191-18-029082-index.htm